The control of hepatic glycogen metabolism in an in vitro model of sepsis.
Culturing hepatocytes with a combination of LPS, TNF-alpha, IL-1beta and IFN-gamma resulted in an inhibition of glucose output from glycogen and prevented the repletion of glycogen in freshly cultured cells. The reduced glycogen mobilisation correlated with the lower cell glycogen content and reduced rate of glycogen synthesis from [U-(14)C]glucose rather than alterations in either total phosphorylase or phosphorylase a activity. There was no change in the percentage of glycogen exported as glucose nor the production of lactate plus pyruvate indicating that redistribution of the Gluc-6-P cannot explain the failure of the liver to export glucose. Although changes in glycogen mobilisation correlated with NO production, inhibition of NO synthase by inclusion of L-NMMA in the culture medium failed to prevent the inhibition of either glycogen accumulation or mobilisation by the proinflammatory cytokines, precluding the involvement of NO in this response. LPS plus cytokine treatment had no effect on total glycogen synthase activity although the activity ratio was lowered, indicative of increased phosphorylation. The inhibition of glycogen synthesis correlated with a fall in the intracellular concentrations of Gluc-6-P and UDP-glucose and in the absence of measured changes in kinase activity, it is suggested that the fall in Gluc-6-P reduces both substrate supply and glycogen synthase phosphatase activity. The fall in Gluc-6-P coincided with a reduction in total glucokinase and hexokinase activity within the cells, but no significant change in either the translocation of glucokinase or glucose-6-phosphatase activity. This demonstrates direct cytokine effects on glycogen metabolism independent of changes in glucoregulatory hormones.
Wallington
Jennifer
J
Biochemistry and Biomedical Science Division, Department of Chemistry and Biochemistry, School of Life Sciences, University of Sussex, Brighton BN1 9QG, UK.
Ning
Jian
J
Titheradge
Michael Alan
MA
D000263:Adenylate Kinase / Q000378:metabolism; D000818:Animals; D016207:Cytokines / Q000494:pharmacology; D004195:Disease Models, Animal; D005947:Glucose / Q000378:metabolism; D019298:Glucose-6-Phosphate / Q000378:metabolism; D024981:Glycogen Phosphorylase / Q000378:metabolism; D006006:Glycogen Synthase / Q000378:metabolism; D038362:Glycogen Synthase Kinase 3 / Q000378:metabolism; D050261:Glycogenolysis / Q000187:drug effects; D006801:Humans; D019344:Lactic Acid / Q000378:metabolism; D008070:Lipopolysaccharides / Q000494:pharmacology; D008099:Liver / Q000187:drug effects / Q000201:enzymology; D008112:Liver Glycogen / Q000378:metabolism*; D008297:Male; D010766:Phosphorylation / Q000187:drug effects; D011494:Protein Kinases / Q000378:metabolism; D019289:Pyruvic Acid / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D018805:Sepsis / Q000378:metabolism*; D014532:Uridine Diphosphate Glucose / Q000378:metabolism; D019323:omega-N-Methylarginine / Q000494:pharmacology
D016207:Cytokines; D008070:Lipopolysaccharides; D008112:Liver Glycogen; D019323:omega-N-Methylarginine; D019344:Lactic Acid; D019298:Glucose-6-Phosphate; D019289:Pyruvic Acid; D024981:Glycogen Phosphorylase; D006006:Glycogen Synthase; D011494:Protein Kinases; D038362:Glycogen Synthase Kinase 3; D000263:Adenylate Kinase; D005947:Glucose; D014532:Uridine Diphosphate Glucose